Genetic Clonality as the Hallmark Driving Evolution of Non-Small Cell Lung Cancer

被引:8
|
作者
Nicos, Marcin [1 ]
Krawczyk, Pawel [1 ]
机构
[1] Med Univ Lublin, Dept Pneumonol Oncol & Allergol, PL-20954 Lublin, Poland
关键词
NSCLC; tumor evolution; driver mutations; clonal; subclonal alterations; metastases; STEM-CELLS; INTRATUMOR HETEROGENEITY; MESENCHYMAL TRANSITION; TUMOR EVOLUTION; BRANCHED EVOLUTION; BRAIN METASTASES; T790M MUTATION; CD133(+) CELLS; ADENOCARCINOMA; NOTCH;
D O I
10.3390/cancers14071813
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Limited knowledge about NSCLC evolution has affected therapeutic strategies for many decades. The application of NGS-based techniques to studies on ITH has provided genetic insight into the contribution of clonality primary seeding, as well as to distant dissemination. To date, multiregional ITH affects accurate diagnosis and treatment decisions and is considered the main hallmark of anticancer therapy failure. Understanding the evolutionary trajectories that drive the metastatic process is critical for improving treatment strategies for this deadly condition. In this review, we discuss how the clonality of genetic alterations influence the seeding of primary and metastatic lesions of NSCLC, highlighting that wide genetic analyses may reveal the phylogenetic lineages of NSCLC evolution. Data indicate that many driver alterations from the primary tumor of non-small cell lung cancer (NSCLC) are predominantly shared across all metastases; however, disseminating cells may also acquire a new genetic landscape across their journey. By comparing the constituent subclonal mutations between pairs of primary and metastatic samples, it is possible to derive the ancestral relationships between tumor clones, rather than between tumor samples. Current treatment strategies mostly rely on the theory that metastases are genetically similar to the primary lesions from which they arise. However, intratumor heterogeneity (ITH) affects accurate diagnosis and treatment decisions and it is considered the main hallmark of anticancer therapy failure. Understanding the genetic changes that drive the metastatic process is critical for improving the treatment strategies of this deadly condition. Application of next generation sequencing (NGS) techniques has already created knowledge about tumorigenesis and cancer evolution; however, further NGS implementation may also allow to reconstruct phylogenetic clonal lineages and clonal expansion. In this review, we discuss how the clonality of genetic alterations influence the seeding of primary and metastatic lesions of NSCLC. We highlight that wide genetic analyses may reveal the phylogenetic trajectories of NSCLC evolution, and may pave the way to better management of follow-up and treatment.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Surgical Treatment of Extrapulmonary Oligometastatic Non-small Cell Lung Cancer
    Ploenes, Till
    Osei-Agyemang, Thomas
    Krohn, Alexander
    Passlick, Bernward
    INDIAN JOURNAL OF SURGERY, 2015, 77 : S216 - S220
  • [42] Role of Rock 1 protein in non-small cell lung cancer
    Yan, Shao-hua
    Gao, Hai-Cheng
    Meng, He-yu
    Cheng, Long
    Zhe, Lv
    Cao, Guo-shen
    Yan, Wei-qun
    Xin, Hua
    BIOMEDICAL RESEARCH-INDIA, 2017, 28 (06): : 2530 - 2534
  • [43] ALK inhibitors and advanced non-small cell lung cancer (Review)
    Rossi, Antonio
    Maione, Paolo
    Sacco, Paola Claudia
    Sgambato, Assunta
    Casaluce, Francesca
    Ferrara, Marianna Luciana
    Palazzolo, Giovanni
    Ciardiello, Fortunato
    Gridelli, Cesare
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (02) : 499 - 508
  • [44] Clinical applications of circulating biomarkers in non-small cell lung cancer
    Oh, Hyun-Ji
    Imam-Aliagan, Abdulhamid B.
    Kim, Yeo-Bin
    Kim, Hyun-Jin
    Izaguirre, Issac A.
    Sung, Chang K.
    Yim, Hyungshin
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [45] Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer
    Haghgoo, Seyyed Mortaza
    Allameh, Abdolamir
    Mortaz, Esmaeil
    Garssen, Johan
    Folkerts, Gert
    Barnes, Peter J.
    Adcock, Ian M.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2015, 754 : 88 - 97
  • [46] TGFβ pathway inhibition in the treatment of non-small cell lung cancer
    Eser, Pinar O.
    Janne, Pasi A.
    PHARMACOLOGY & THERAPEUTICS, 2018, 184 : 112 - 130
  • [47] Molecular testing in non-small cell lung cancer: A consensus recommendation
    Lai, Gillianne Geet Yi
    Cheng, Xin Min
    Ang, Yvonne Li'en
    Chua, Kevin Lee Min
    Samol, Jens
    Soo, Ross
    Tan, Daniel Shao Weng
    Lim, Tony Kiat Hon
    Lim, Darren Wan Teck
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2023, 52 (07) : 364 - 373
  • [48] Metformin for non-small cell lung cancer patients: Opportunities and pitfalls
    Levy, Antonin
    Doyen, Jerome
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 125 : 41 - 47
  • [49] Gemcitabine in non-small cell lung cancer (NSCLC)
    Manegold, C
    Zatloukal, P
    Krejcy, K
    Blatter, J
    INVESTIGATIONAL NEW DRUGS, 2000, 18 (01) : 29 - 42
  • [50] The Adenosinergic Pathway in Non-Small Cell Lung Cancer
    Van Kerkhove, Olivier
    Verfaillie, Saartje
    Maes, Brigitte
    Cuppens, Kristof
    CANCERS, 2024, 16 (18)